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Simple Summary: Hyperthermia is a treatment for cancer patients, which consists of heating the
body to 43 ◦C. The temperature during treatment is usually measured by placing temperature probes
intraluminal or invasively. The only clinically used option to measure temperature distributions
non-invasively and in 3D is by MR thermometry (MRT). However, in order to be able to replace
conventional temperature probes, MRT needs to become more reliable. In this review paper, we pro-
pose standardized performance thresholds for MRT, based on our experience of treating nearly
4000 patients. We then review the literature to assess to what extent these requirements are already
being met in the clinic today and identify common problems. Lastly, using pre-clinical results in
the literature, we assess where the biggest potential is to solve the problems identified. We hope
that by standardizing MRT parameters as well as highlighting current and promising developments,
progress in the field will be accelerated.
Abstract: Hyperthermia treatments in the clinic rely on accurate temperature measurements to guide
treatments and evaluate clinical outcome. Currently, magnetic resonance thermometry (MRT) is
the only clinical option to non-invasively measure 3D temperature distributions. In this review,
we evaluate the status quo and emerging approaches in this evolving technology for replacing
conventional dosimetry based on intraluminal or invasively placed probes. First, we define standard-
ized MRT performance thresholds, aiming at facilitating transparency in this field when comparing
MR temperature mapping performance for the various scenarios that hyperthermia is currently
applied in the clinic. This is based upon our clinical experience of treating nearly 4000 patients with
superficial and deep hyperthermia. Second, we perform a systematic literature review, assessing
MRT performance in (I) clinical and (II) pre-clinical papers. From (I) we identify the current clinical
status of MRT, including the problems faced and from (II) we extract promising new techniques
with the potential to accelerate progress. From (I) we found that the basic requirements for MRT
during hyperthermia in the clinic are largely met for regions without motion, for example extremities.
In more challenging regions (abdomen and thorax), progress has been stagnating after the clinical
introduction of MRT-guided hyperthermia over 20 years ago. One clear difficulty for advancement is
that performance is not or not uniformly reported, but also that studies often omit important details
regarding their approach. Motion was found to be the common main issue hindering accurate MRT.
Based on (II), we reported and highlighted promising developments to tackle the issues resulting
from motion (directly or indirectly), including new developments as well as optimization of already
existing strategies. Combined, these may have the potential to facilitate improvement in MRT in the
form of more stable and reliable measurements via better stability and accuracy.
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1. Introduction
Hyperthermia (39–43 ◦C) has been successful as a cancer treatment due to several
beneficial effects on tissue, such as enhancing the efficacy of radiotherapy and chemother-
apy [1,2]. The hallmarks of hyperthermia have been identified and are comprehensively
presented by Issels et al. [3]. Due to these benefits, paired with no major side effects,
hyperthermia has established itself in the clinic for many tumor sites [4–7]. Dose–effect
studies show a positive association between thermal dose parameters and clinical out-
come, which implies that real-time temperature dosimetry is essential [8–14]. Temperature
during treatment is traditionally monitored by probes inside catheters that are placed
inside lumina or pierced into tissue. These provide information at a limited number of
points and may be difficult or unfeasible to place, or associated with complications [15,16].
Magnetic resonance thermometry (MRT) can provide a real-time 3D temperature map in
a non-invasive way (Figure 1) and hence has the potential to make hyperthermia safer
for the patient. Visualizing what is heated and to what extent is a necessary first step to
be able to not only control hot spots in normal tissue and adapt to cold spots in tumor
tissue, but also provide the means to perform a repeatable measurement, as well as to
investigate the true optimum temperature for maximizing clinical outcome. MRT has been
shown to correlate with pathological response in soft-tissue sarcomas of prospectively
registered patients [17]. Despite this potential, MRT thus far has failed to establish itself as
the standard temperature measurement method in hyperthermia treatments. Given the
continued reported progress in the pre-clinical setting, we hypothesize that a major cause
of this stagnation is the unclear validation status, as well as the non-standardized way of
reporting pre-clinical performance. There is currently no overview of the clinical status
quo of MRT in hyperthermia, and promising technologies are difficult to spot in the jungle
of performance indicators. Further, the substantial financial investment will be overcome
once the full contribution of MRT to hyperthermia quality is convincingly shown.
There have been many successful attempts to review the field. Rieke et al. [18] gives
an overview of the different magnetic properties that can be exploited to obtain MRT. The
importance of accuracy and stability of thermometry measurement are stressed, and ac-
quisition and reconstruction methods that reduce motion artefacts are highlighted. Winter
et al. [19] is expanding on those challenges faced, also supplying possible solutions. In ad-
dition to the hurdles, the implicit nature of the requirements for adequate MR temperature
mapping during hyperthermia treatments complicates this quest. Different MRT techniques
have different drawbacks and are thus suitable for different purposes of application. One
example is the proton resonance frequency shift (PRFS), which is most frequently used to
measure temperature due to its linear variability with temperature and, with the exception
of fat, tissue independence. As the investigated shifts are very small, they are not easily
able to deal with physiological changes, hence accurate temperature measurements are
hampered by changes in the microenvironment of the tissue, for example in flow, oxygen
levels, perfusion and magnetic properties of the blood. Lüdemann et al. [20] compared
MRT techniques and their achievable accuracies. Despite these excellent reviews in the
field, there has not been a comprehensive analysis of the validation status and a ranking of
the pre-clinical work based on a clear set of performance indicators.
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For patients to benefit from MRT in hyperthermia treatments, it needs to become re-
liable so that the invasive probes are no longer needed. Our objective is to identify how 
MRT can be improved to a point where the added value is appreciated in the clinic, lead-
ing to a more widespread use. In order to aid this development, we will firstly define 
minimum requirements for a successful treatment, creating a benchmark for more uni-
form reporting and clear comparisons across studies. Secondly, after a systematic litera-
ture search, clinical data will be used to assess to what extent the MRT performance met-
rics obtained satisfy these requirements. This will be used to identify areas of insuffi-
ciency, but also areas of overlap and common concerns. Finally, we will use pre-clinical 
data from the literature search to identify new techniques, which address those common 
concerns. By highlighting these ‘most promising to advance the field’ publications, we 
hope to emphasize the direction for future research and thus accelerate progress further. 
 
Figure 1. Taken from Gellermann et al. [21] and re-printed with permission from John Wiley and Sons. Example of anat-
omy with thermal mapping catheters (red arrows) for two patients with corresponding MR temperature distributions for 
three different slices. The images were acquired with a T1-weighted gradient-echo sequence. (The arrows were superim-
posed on the original image for clarity.) 
2. Minimum Recommended Clinical MRT Performance 
There are a lot of performance measures that can be evaluated and reported on, 
which in turn depend on many different acquisition settings. To clarify the situation, we 
introduce the most important acquisition parameters and state which MRT performance 
measures are vital to report on and define what minimum values we consider acceptable, 
based on the group’s expertise in nearly 4000 clinical (superficial and deep) hyperthermia 
treatments [6,9,22]. Our aim is to create a clear list of requirements of what is needed from 
a clinical MR guided hyperthermia treatment perspective. The focus is on MRT for mild 
and moderate hyperthermia (39–43 °C) only, hence excluding ablative temperatures. The 
latter has been the aim for most techniques, since MR guided thermal ablation has a much 
Figure 1. Taken from Gellermann et al. [21] and re-printed with permission from John Wiley and Sons. Example of anatomy
with thermal mapping catheters (red arrows) for two patients with corresponding MR temperature distributions for three
different slices. The images were acquired with a T1-weighted gradient-echo sequence. (The arrows were superimposed on
the original image for clarity.)
For patients to benefit from MRT in hyperthermia treatments, it needs to become
reliable so that the invasive probes are no longer needed. Our objective is to identify
how MRT can b impr ved to a point where the added value is app eciated n the clinic,
leading to a more widespread use. In order to aid hi development, we will firstly defin
inimum requ rements f a successful treatment, creating a benchmark for more uniform
reporting and clear compariso s across studies. Secondly, after a systematic literature
search, clinical data will be used to assess to what extent the MRT performance metrics
obtained satisfy these requirements. This will be used to identify areas of insufficiency,
but als areas of overlap and common concerns. Finally, we will use pre-clinical data from
the literatur search to identify new techniques, which address those common concerns.
By highlighting these ‘most promising to advance the field’ publications, we hope to
emphasize the direction for future research and thus accelerate progress further.
2. Minimum Recommended Clinical MRT Performance
There are a lot of performance measures that can be evaluated and reported on,
which in turn depend on many different acquisition settings. To clarify the situation, we
introduce the most important acquisition parameters and state which MRT performance
measures are vital to report on and define what minimum values we consider acceptable,
based on the group’s expertise in nearly 4000 clinical (superficial and deep) hyperthermia
treatments [6,9,22]. Our aim is to create a clear list of requirements of what is needed
from a clinical MR guided hyperthermia treatment perspective. The focus is on MRT for
mild and moderate hyperthermia (39–43 ◦C) only, hence excluding ablative temperatures.
The latter has been the aim for most techniques, since MR guided thermal ablation has
a much wider use. Compared to ablation, temperature changes in mild and moderate
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hyperthermia are slow (approximately 10–30 min to reach the target temperature), target
regions are generally large, and the temperature changes from baseline are low (2–8 ◦C).
Consequently, the desired temperature mapping performances are also different: although
spatial resolution may be lower, measurement accuracy and stability (temporal temperature
precision) must be high and robustness against confounders much better.
The minimum acquisition parameters we recommend for successful MRT are reported
in Table 1 and the minimum MRT performances are shown in Table 2.
Table 1. Minimum acquisition parameters, such that successful MRT in hyperthermia can be
achieved.
Parameter Definition Minimum
Spatial resolution In-plane resolution times slice width(2D) or through-plane resolution (3D) 125 mm
3
Temporal resolution Time needed to acquire one MRT slice 20 s
Table 2. Minimum performance metrics for successful MRT in hyperthermia treatments.
Measure Metric Definition Minimum
































∣∣∣Ej − A∣∣∣ ≤1 ◦C
Considering the large areas of heating in hyperthermia and consequently low ther-
mal gradients, we consider a reasonable minimum spatial and temporal resolution to be
125 mm3 (for instance 5 × 5 × 5 mm3). A higher spatial resolution may be required to
achieve acceptable accuracy, by avoiding partial volume effects in regions with many small
and contrasting tissues.
For this recommendation, we also considered the current spatial resolution that
is achieved with invasive thermometry. In general, the distance between measuring
points along a thermometry catheter track is 1–2 cm. The distance between thermometry
catheters is much larger still, in the range of 5–10 cm. Additionally, the MRT resolution
should be considered with respect to the resolution of our ability to steer the energy
distribution. At this moment, the focus of the 100 MHz RF-deep heating has a diameter
of 7–14 cm. For the Hypercollar3d operating at 434 MHz, this is 3 cm. Finally, when
utilizing hyperthermia treatment planning for deep as well as head and neck treatments,
the CT images used for planning are acquired with a slice width of 5 mm and a resolution
of 0.98 mm in both x and y [23]. It is also worth considering that a higher resolution in
hyperthermia treatment planning comes at the cost of increased intricacy and treatment
time [24].
For deep heating, the clinical objective is to achieve a temperature increase between
0.5 and 2 ◦C per 5 min. If it is lower (<0.5 ◦C), the power is increased in order to speed
it up; if it is higher (>2 ◦C), the power is reduced to slow it down. Because of these
relatively slow heating times and the resulting high time constant of thermal washout,
the minimum temporal resolution should be 20 s. This recommended minimum of the
temporal resolution concerns the minimum acceptable time from a clinical perspective,
and faster scanning may be required in regions of motion to achieve acceptable accuracy.
Another reason to speed up the acquisition may be when the averaging of temperature
data is required to achieve the minimum MRT performance, as stated in Table 2.
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Regarding the important performance measures, the first mentioned in Table 2 is bias,







(Ej − A) (1)
This is the difference between the MRT measurement (Ej) and another temperature
measurement that is considered true (A) over all measured time points (n). This reference
A, i.e., the gold standard, can be a set of invasive temperature probes, or another MRT
map originating from a well-established sequence. It is important to have a reliable and
repeatable MRT readout, without a systematic over- or underestimation of temperature,
translating to a low bias in measurements. Curto et al. made a comparison of the currently
worldwide installed five RF-MR hybrid systems in anthropomorphic phantoms, showing
with a mean error as low as 0.13 ◦C can be achieved with current systems in ‘ideal condition’
pre-clinical settings [26]. In light of the best resolution available, we consider a ME of
≤|0.5 ◦C| to be appropriate.
The following two measures, defined in Table 2, are spatial and temporal temperature
precision. The spatial temperature standard deviation (SD) reflects the variability in
the region of temperature evaluation, consisting of a ROI. Spatial temperature SD of
the ROI evaluated should be ≤0.5 ◦C in order to guarantee that the noise present is
not too large and there are no large temperature gradients within the heated region;
in other words, the heated region is sufficiently uniform. Temporal temperature SD
assesses the variability of the spatial mean temperature in a ROI across all time points and
indicates the repeatability and stability of the measurement. Considering treatment times
are long, but keeping in mind the importance of staying in the target temperature zone,
the temporal temperature precision should not exceed 0.5 ◦C (after drift correction) for
a 90 min thermometry measurement. Both the spatial and temporal temperature SD are
influenced by the size and location of the ROI chosen. This, in turn, is highly dependent
on the MRT region imaged, as areas with poor uniformity (for example near tissue/air
boundaries) need to be avoided for sufficient accuracy of the measurement. Due to this
needed flexibility, no recommendation on size and location of the ROI will be stated.
In order to fulfil the minimum requirement of the temperature precision defined above,
the ROI should be chosen with care in a region as uniform as possible. The measures of
temperature precision are only valuable when the ROI is kept constant throughout the
measured time points.
The final performance measure that is vital to report on is the accuracy of the MRT
measurement. Accuracy, as stated by Walther et al. [25], can either be presented as the
mean squared error (MSE), the root mean squared error (RMSE) or the mean absolute error
(MAE). We consider the MAE the best one for our application since it is less sensitive for







∣∣Ej − A∣∣ (2)
where Ej is the MRT measurement, A is another temperature measurement that is con-
sidered true and n is the number of all measured time points. Given the importance of
keeping to the right heating range for the desired physiological changes in the tumor tissue,
we think it should be ≤1 ◦C.
3. Methods
3.1. Literature Search
In order to ensure that all papers published using MRT in hyperthermia treatments will
be included, a logical search string was defined including a hyperthermia term, a magnetic
resonance thermometry term, and excluding ablation in a major term. The search strings
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used for the different databases are provided in Appendix A. We searched the databases
for papers published from inception of the databases until 24 November 2020. Details on
the number of results obtained from the respective data bases are presented in Table A1.
Using the method from Wichor et al. [27], all papers were screened by title and
abstracts for relevancy to our topic. At this stage, papers were excluded if they were not
published in English, if they were not research articles or if the topic was not related to MRT
in hyperthermia. Our definition of the combination of mild and moderate hyperthermia
includes treatments with the heating goal between 39 and 45 ◦C. We acknowledge that in
some cases tumor temperatures can be higher than the target temperature, thus papers up
to 47 ◦C were considered relevant.
The resulting 218 relevant papers were then assessed for eligibility, using the following
exclusion criteria: (#1) ex-vivo results, (#2) not original data, and (#3) small animals.
Ex vivo results excluded studies on simulation or phantoms, which we considered too far
from the final intended use of the clinic to be included in this review. No original data
excluded reviews and studies using already published data as reference. Small animals
were considered to be anything smaller than a dog. These studies were excluded because
we deem these data not predictive for humans due to the different motion profile (e.g.,
faster heart rate) and their smaller size. Additionally, the equipment used is specially made
and non-clinical, lowering the ease of translation into the clinic. Large animal studies
without heating were also not included. After this eligibility assessment, 43 papers remain
to be included in the systematic analysis. A PRISMA flow chart of the exclusion process is
shown in Figure 2.
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3.2. Categories and Classification
The studies included were then categorized into patients with treatment intent and
pre-clinical groups (with no hyperthermia treatment intent). Peller et al. [28] included
treated and non-treated patients and thus was allocated to both groups. Clinical studies
included 10 studies. Pre-clinical studies consisted of 35 studies: 26 papers with human
subjects and 12 studies including large animals. In early volunteer studies, heating and
cooling were sometimes applied to the volunteers without therapeutic intend. These
studies were also considered pre-clinical.
The relevant papers were read in detail and relevant data were extracted into Mi-
crosoft Excel tables. The information, such as first author and year of publication, is the
one obtained from the EndNote library. Other study data considered relevant were: hyper-
thermia treatment approach, imaging setup, MRT performance and the exclusion of data.
Pre-clinical papers were also grouped and ranked based on their main aim and achieved
improvement to identify promising techniques. Large animals, volunteers and non-heated
patients are easier to image than treated patients, making it more likely for their MRT
data to be artefact free. Large animals are typically sedated and mechanically ventilated
during treatment, which reduces their breathing and makes it more predictable, and also
lowers their blood perfusion. Muscle relaxant and bowel movement suppressants are also
administered, minimizing any other avoidable motion. Volunteers have the advantage of
no initial stress from illness and, when there is no heat applied, no additional stress during
the treatment. Non-treated patients also lack the additional stress of treatment. Except for
these differences, both large animals and volunteers have similar confounders such as size,
motion profile and they generally use the same equipment for heating as well as imaging.
Thus we consider these pre-clinical studies predictive for the reproducibility in patients
during treatment.
4. MRT Performance in Clinical Studies
4.1. Status
MRT in hyperthermia is predominantly used for extremities (67%) and some studies
investigated it in the pelvis (33%). This trend can be explained by the absence of motion
and resulting artefacts in extremities. Data of ongoing research in our group show that
achieving successful MRT in the pelvic area is much harder than in more static regions of the
body. The average maximum temperature achieved during the hyperthermia treatments
was 43.8 ◦C, which is well within the target treatment temperature range, and the treatment
time varied from 30 to 90 min. All studies applied hyperthermia using radiofrequency
(RF) electromagnetic waves. The most popular system is the BSD2000/3D/MR, which
incorporates the twelve channel Sigma Eye applicator.
The imaging setup for the 10 clinical studies is presented in Table 3. The published
MRT in hyperthermia clinical experience is limited to very few centers (Duke, Tubingen,
Berlin, Munich). Hence there is a challenge on translating their high degree of specific
experience to other centers. Additionally, it is difficult to define a benchmark due to the
limited amount of data published.
The imaging coil used by most was the body coil, so when this information was
absent, the body coil was assumed. MRT was based on the proton resonance frequency
shift (PRFS), except in Peller et al. [28], who used T1. This is not surprising, as PRFS
varies linearly with temperature over an adequate range and is near independent of tissue
type [29]. Gradient Recalled Echo (GRE) sequences were generally used (Table 3), and all
sequences acquired 2D MRT maps. Peller et al. [28] was the only study which used a
0.2 Tesla MRI instead of 1.5 T. The frequency of MRT acquisition varied from continuous to
every 20 min. Studies that reported values for spatial and temporal resolutions within our
recommended minimum of 125 mm3 and 20 s are shaded in green in Table 3. Most studies
manage to satisfy the minimum requirements, as defined in Tables 1 and 2.
Methods used to improve the thermometry quality were:
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 Increasing the number of excitations (NEX) > 1 (number of times each k-space line is
read) [30,31].
 Applying flow compensation [32].
 Including modelling of blood perfusion [33].
 Using background field removal algorithms to correct for motion-induced susceptibil-
ity artifacts [34].
 Only selecting evaluable volumes or treatments—all but one study (discussed in
“Exclusion” section below).
Table 3 also shows the MRT performance reported in clinical papers. Values that meet
our minimum requirements are shaded in green. Of the metrics that are reported, 6/9 of
studies (67%) satisfy one or more of our minimum requirements.
Unsoeld et al. [17] shows the correlation of measured temperature with clinical out-
come. Whilst this study investigates the true goal of the treatment, this study could have
contributed more to the field if it had also reported bias, temperature SD and accuracy.
This would have helped to understand the required treatment quality and the relationship
between thermal dose and treatment outcome. A similar line of thought applies to the
study of Wu et al. [34], which gives accounts of TNR improvement from their investigated
correction method, but neglects to quantify these. Table 3 demonstrates that few perfor-
mance metrics are reported, which makes it difficult to compare the status of MRT between
different studies. Additionally, definitions of parameters are often lacking, leading to the
need for educated guesses.
4.2. Exclusion of Data
Comparing these indicative performance metrics listed above comes with limitations.
Often even the ROIs considered within the same study at different time points are not
constant. Additionally, certain numbers of time points were often excluded from the
evaluation—usually due to image artefacts that produce noisy thermometry maps. This
decrease in the number of thermometry maps adds selection bias to the performances
reported. In Table 4, we present what data were excluded post-acquisition and the reason
why the authors excluded the data. If exclusion was not explicitly mentioned, we assumed
that all MRT data acquired were also included in the analysis.
As is shown in Table 4, only one study included all of the acquired MRT data. This
apparent need to exclude data underlines the need for MRT to become more reliable in
regions of motion before it can replace invasive temperature probes. Information on the
total study sizes also provides objective information on the practicality of using MRT.
The limited number of publications on clinical use of MRT is highlighted and confirms
that experience is very local (and presumably the conclusion on the feasibility of MRT is
biased by the positive attitude of the researchers). All of the above clearly demonstrates
that MRT is still in a developing phase and there exists a substantial need to make major
improvements to expand to broader use of the technology.
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Table 3. Imaging setup for clinical papers.





◦C) Spatial TemperaturePrecision (◦C)
Temporal Temperature
Precision (◦C) MAE (
◦C)
Carter (1998) [35] E GRE 8.8 - - 0.50 - -
Craciunescu (2009) [31] E GRE 27.4 10 - 0.52 - 0.74
Craciunescu (2001) [33] † E GRE 11.9 - - 0.49~ - -
E GRE 13.7 - - 0.56~ - -
EPI 156.0 1
Dadakova (2015) [32] E,P EPI 67.6 1.08 −0.04 0.55 - 0.40
GRE 152.1 3.12
Gellermann (2005) [36] P GRE 146.8 3.12 - 2.10 - 1.50
Gellermann (2006) [21] E,P GRE 146.8 3.12 1.10 0.70 - -
Peller (2002) [28] *,ˆ E,P GRE 96.1 64 - 0.10 - -
Stauffer (2009) [30] E GRE 21.1 15 0.85 - - -
Unsoeld (2020) [17] E not stated - - - 0.21 - -
Wu (2020) [34] P GRE 152.1 3.32 - - - -
† Supplied a 95% confidence interval of the MR temperature. * Used T1 instead of PRFS for calculating MR temperature maps. ˆ Uses a 0.2 T instead of a 1.5 T MRI. ~ Standard error
instead of SD. Body part imaged: E = extremities, P = pelvis. Metrics that are within our recommended minimum are shaded in green (spatial and temporal resolutions of 125 mm3 and
20 s, respectively).
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Table 4. Exclusions of data from clinical studies post-acquisition.
Author All Data included? Size of Study What Was Excluded? Why?
Carter (1998) [35] No 4 patients5 treatments Not stated Artefacts
Craciunescu (2001) [33] Yes 2 patients - -
Craciunescu (2009) [31] No 10 patients40 treatments
4 patients
12 treatments
Lack of MR information in HT
treatments
performed outside the MR scanner,
image/motion artefacts,
uncorrectable drift, impossibility to
localize the fiber optic probes,
missing/corrupted data files
Dadakova (2015) [32] No 3 patients20 treatments
1 patient
1 treatment
Susceptibility artefact in the ROI
from air in rectum
Gellermann (2005) [36] No 15 patients Everything but 1 bestsession per patient
MR data sets incomplete and/or
disturbed by technical reasons
Gellermann (2006) [21] No 9 patients30 treatments 15 treatments
Breakdown or malfunction of
applicator, restlessness of the patient
Peller (2002) [28] No 1 patient “Data sets” Artefacts




Uncorrected field drift or inability to
locate or correlate sensor positions
or significant patient position shift
early in treatment
Unsoeld (2020) [17] No 24 patients
13 patients: 11 patients
with abdominal and
pelvic tumors; 1 patient
with different time
course of therapy; 1
patient without surgery
Breathing and intestinal motion
artefacts in MRT data; pathological
response is not comparable; lack of
information on pathological
response
Wu (2020) [34] No 4 patients 2 patients
Bulk motion due to discomfort
during treatment, ROI contained too
much gas
4.3. Pre-Clinical Status—How Does It Compare?
Comparing their imaging setup, pre-clinical studies are very similar to clinical ones.
The sequences used and MRT methods used were more varied, but just like the patient
studies investigated, the spatial resolution was met in all studies and temporal resolution
requirement was met in 29/35 studies. Regarding MRT performance metrics about half
of the pre-clinical studies achieved our minimum requirements. This is illustrated and
contrasted to the clinical performance in Figure 3.





Figure 3. Performance values reported and how many of those satisfied our requirements for clinical and pre-clinical 
studies. 
Considering exclusion of data post-acquisition, five pre-clinical studies (two with 
large animal and three with human subjects) excluded some, which is significantly less 
than the clinical studies investigated. This most likely can be linked back to the subjects 
making measurement conditions less challenging, as mentioned above. 
4.4. New Techniques and Their Improvement 
Table 5 presents the main techniques and methods investigated in the pre-clinical 
studies and their found improvement over standard methods. From this information, we 
have identified common main aims (last column). 
Table 5. Pre-clinical studies by the year of publication; including technique/method investigated, improvement found 
(where applicable) and main aim of the study. Feasibility and comparison studies are presented in grey. Studies satisfying 
our performance criterion are highlighted in green. 
Author Year Technique/Method Investigated Improvement Main Aim 
Wu [34] 2020 
Correction of motion-induced sus-
ceptibility artifacts 
TNR improvement 
B0 changes and im-
age gaps due to mo-
tion, B0 drift 
Ferrer [37] 2020 Different B0 drift corrections 
IQR improved from 9.31 to 
0.80 °C. ME improved from 
−4.30 to 0.33 °C 
B0 drift 
Bing [38] 2019 Forced breath-hold MR-HIFU 
Accuracy and stability from 
1.2 to 0.6 °C and from 1.4 to 
0.8 °C 
B0 changes and im-
age gaps due to mo-
tion 
Odeen [39] 2019 
Different protocols for PRFS MRT 
for LITT 
Factor 2 improvement in the 
temperature SD 
Comparison 
Tan [40] 2019 
Motion compensation using prin-
cipal component analysis and pro-
jection onto dipole fields 
Reduces temperature SD from 
3.02 to 0.86 °C 
B0 changes and im-
age gaps due to mo-
tion 
Wu [41] 2019 Novel fast spin echo method 
TNR efficiency improved by 
25%  
Feasibility 





























ME ≤ |0.5°C| SD  ≤ 0.5°C MAE ≤ 1°C
satisfied not satisfied not reported
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studies.
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i
4.4. New Techniques and Their Improvement
Table 5 presents the main techniques and methods investigated in the pre-clinical
studies and their found improvement over standard methods. From this information,
we have identified common main aims (last column).
Table 5. Pre-clinical studies by the year of publication; including technique/method investigated, improvement found
(where applicable) and main aim of the study. Feasibility and comparison studies are presented in grey. Studies satisfying
our perfor ance criterion are highlighte in green.
Author Year Technique/MethodInvestigated Improvement Main Aim
Wu [34] 2020 Correction of motion-inducedsusceptibility artifacts TNR improvement
B0 changes and i age gaps
due to motion, B0 drift
Ferrer [37] Different B0 drift corrections
IQR improved from 9.31 to 0.80
◦C. ME improved fr m −4.30 to
0.33 ◦C
B0 drift
Bing [38] 2019 Forced breath-hold MR-HIFU Accuracy and stability from 1.2to 0.6 ◦C and from 1.4 to 0.8 ◦C
B0 changes and image gaps
due to motion
Odeen [39] 2019 Different protocols for PRFSMRT for LITT
Factor 2 improvement in the




and projection onto dipole fields
Reduces temperature SD from
3.02 to 0.86 ◦C
B0 changes and image gaps
due to motion
Wu [41] 2019 Novel fast spin echo method TNR efficiency improved by 25% Feasibility
Zhu [42] 2019 Feasibility/safety of MRgHIFU N/A Feasibility
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Table 5. Cont.
Author Year Technique/MethodInvestigated Improvement Main Aim
Jonathan [43] 2018
Proposed and validated a hybrid
radial-EPI temperature mapping
pulse sequence
Provides whole brain coverage,
temperature SD was 48% higher
than standard
Feasibility





Precision and stability of
temperature improved from 7.8
and 2.3 ◦C to 0.3 and 0.6 ◦C
Feasibility
Svedin [46] 2016
Correction of respiration artifact
in 3D MRT using phase
navigators
Temperature measurement
improved by a factor of 2.1
B0 changes and image gaps
due to motion
Tillander [47] 2016 Hyperthermia for deep-seatedheating volumes using HIFU N/A Feasibility
Boulant [48] 2015
FID navigator to correct for B0
field and variations induced by
breathing
Reduces the temperature SD of
the data over the first 8 min from
0.2 to 0.05 ◦C
B0 drift and B0 changes
due to motion
De Senneville [49] 2015 Approach for motion estimationof abdominal organs
Temperature SD improvement of
0.4 ◦C and reduction of artefacts
by up to 3 ◦C
B0 changes and image gaps
due to motion
Gaur [50] 2015 Reconstruction method toaccelerate MRT
Achieves same temperature
error at up to 32× acceleration
factors
Acceleration
Marx [51] 2015 MASTER sequence Temperature SD improvementfrom 1.21 to 0.82 ◦C Feasibility
Mei [52] 2015 Different methods for B0inhomogeneity correction None B0 drift
Pichardo [53] 2014 Multi-baseline MR-basedthermometry
Reduced temperature SD from
25.2 to 2.4 ◦C B0 changes due to motion
Shi [54] 2014




Minalga [55] 2013 Integrated multi-channel RFreceive coil with MR-HIFU
163% SNR improvement
averaged over all positions
investigated
Feasibility
Ramsay [56] 2013 Segmented GRE-EPI technique N/A Feasibility
Kickhefel [57] 2010 Comparison of fast sequences Stability improvement from 1.07to 0.21 ◦C Comparison
Wyatt [58] 2010
Correction of breathing-induced
errors using multi-echo fitting
methods
Temperature SD from 2.18 to
0.61 ◦C and bias from 3.17 to
−1.26 ◦C
B0 changes and image gaps
due to motion
Roujol [59] 2009 Reconstruction pipeline foradaptive TSENSE
Image latencies below 90 ms at
frame rates up to 40 images/s Acceleration
Wyatt [60] 2009 Different stabilization strategies Improved error by up to 0.5 ◦C B0 drift
Silcox [61] 2005
Ultrasonic heating to control
transgene expression spatially
using a minimally invasive
approach
N/A Feasibility
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Table 5. Cont.
Author Year Technique/MethodInvestigated Improvement Main Aim
Sun [62] 2005 Adaptive controllers with MRT N/A Feasibility
Peller [28] 2002 Characterize T1 for thermometry N/A Feasibility
Il’yasov [63] 1998 RARE sequence for diffusionMRT N/A Feasibility
Corbett [64] 1997 1H MR spectroscopy to measureabsolute brain temperature N/A Feasibility
MacFall [65] 1996 Chemical shift of water for MRT N/A Feasibility
De Poorter [66] 1995 PRF thermometry in vivo N/A Feasibility
MacFall [67] 1995 Rapid diffusion weighted EPI,being less sensitive to motion
Temperature SD from 1.5 to
0.9 ◦C B0 changes due to motion
Young [68] 1994 Initial investigation of T1dependence, D and perfusion N/A Feasibility
Hall [69] 1990
Investigation which MR
parameter would be best for
MRT in vivo
N/A Comparison
When looking at the improvements mentioned over the benchmark methods (column 4
of Table 5), there was only one study that did not find an improvement in their investigated
techniques (Mei et al. [52]). This demonstrates the importance and success of pre-clinical
work.
The most promising techniques from Table 5 are the 13 studies satisfying our MRT
performance criterion, these are highlighted in green. It can be seen that in recent years
more studies have satisfied these minimum requirements. A total of 8 out of those 13
studies are feasibility or comparison studies (marked in grey in Table 5), which can be
grouped into having investigated:
1. Hardware: MR-HIFU for different treatment location applications [45,47]
2. Thermometry method: MR spectroscopy to measure absolute temperature [64]
3. Sequences and parameters for MRT [43,56,57,70]
4. Performance of MRT at different anatomical sites [71]
The remaining 5/13 pre-clinical studies satisfying our MRT performance criteria and
not involving feasibility or comparisons can be grouped by common main aims or problems
to solve:
1. B0 drift: correction and stabilization strategies [37,60], navigator echoes [48];
2. B0 changes due to motion: breath hold [38], navigator echoes [48];
3. Image gaps due to motion: breath hold [38];
4. Acceleration: reconstruction method [50].
It needs to be highlighted that with the exception of Bing et al. [38], these studies have
investigated only one subject, so their potential needs to be validated on a larger scale.
Despite great potential, the possible limitations of the techniques mentioned above when
transferred to patients in a clinical environment must be mentioned. Breath hold may
not always be a viable option for the clinic. Some patients (for example young children)
may not be able to hold their breath effectively, or may be sedated during the treatment.
Additionally, the total treatment time will lengthen, as the patient needs periods of normal
breathing to recover. Navigators to correct for B0 changes induced by breathing may only
be valuable in areas with no motion in the treated area, as well as very regular breathing
patterns. Similarly, B0 drift corrections may only be valuable in areas with no motion or
motion induced changes present.
It can be seen from the investigated studies that groups working on MRT advances are
generally different groups than those working on patients with a treatment objective. The
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consequence is that solutions are presented with very limited ability to be transferred to
clinical practice in RF-hyperthermia MRT. This is highlighted by the fact that no progress
has been made in MRT for pelvic RF-hyperthermia in the past two decades: the body coil
is still used for imaging and PRFS is used with no real solution for correction of external
and internal movement, for instance by passing air.
However, the technological advances in recent years are promising in many ways.
Multi-coil integrated hyperthermia systems are becoming available and provide much bet-
ter SNR than the commonly used body coil [55,72]. At the same time, multi-coil acquisition
also offers acceleration of MRT by techniques such as, for example, parallel imaging or
compressed sensing [73]. This faster acquisition enables better temperature monitoring,
especially in regions with motion. Additionally, the computational power available now is
much bigger and cheaper compared to only a few years ago, which makes more compli-
cated reconstruction method and correction strategies feasible [34]. Last but not least, new
sequences and approaches are being developed to increase MRT performance and explore
the possibility to perform MRT in more difficult regions. In early years, researchers broadly
investigated different methods of MRT, but PRFS quickly crystalized as the method of
choice for hyperthermia treatments for reasons aforementioned. It is only now, that other
methods are being considered again. Hybrid approaches of PRFS/T1 MRT are just one
method on the horizon that enables temperature mapping in fatty regions [74], which PRFS
alone would be unable to detect.
Considering all these innovations, the present conditions are favorable to push MRT
to the next level and hopefully, in the near future, have the powers to elevate it from a
research modality to clinical practice.
5. Conclusions
Standardized reporting of parameters used and performances obtained in MRT is
important. Hence we defined a minimum benchmark of important performance metrics
including bias, spatial and temporal temperature precision as well as accuracy; these
should be within ≤|0.5 ◦C|, ≤0.5 ◦C, ≤0.5 ◦C and ≤1 ◦C, respectively.
When systematically assessing the literature, we can conclude that MRT performance
in hyperthermia is already achieving most of these requirements for extremities but not yet
in regions with more motion present. Motion as well as the B0 changes, as a direct or indirect
consequence, emerged as the main problem of accurate and reliable MR temperature
measurement.
Various techniques satisfying our performance requirements are already available
at the pre-clinical stage addressing these problems. Most promising common solution
proposals can be divided into either new approaches or optimizations. New approaches
include hardware or software being developed; propitious optimizations include correction
and stabilization strategies, navigator echoes, breath hold and various reconstruction
methods. We anticipate that highlighting these promising pre-clinical advancements will
accelerate the progress of MRT.
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Abbreviations
FOV Field of view
MAE Mean absolute error
ME Mean error
MR-HIFU MR-high intensity focused ultrasound
MRT Magnetic resonance thermometry
MSE Mean squared error
NEX Number of excitations
PRFS Proton resonance frequency shift
RF Radiofrequency
RMSE Root mean squared error
ROI Region of interest
SD Standard deviation
Appendix A. Detailed Search Strings
Table A1. Databases searched for research articles. In brackets is the date of inception of the database.
The 2nd column shows the number of search results and the 3rd column the number of search results
after removing duplicates.
DATABASE Number ofResults
Number of Results after
Removing Duplicates
Embase (1971–) 1292 1345
Medline ALL Ovid (1946–) 723 113
Web of Science Core Collection (1975–) 693 55
Cochrane CENTRAL register of trials (1992–) 21 15
Google scholar 200 147
Total 2929 1675
Original search strings of the respective databases introduced in Figure 2.
Appendix A.1. Embase.com (1971–) 1292
(‘hyperthermia’/de OR ‘thermotherapy’/exp OR ‘high intensity focused ultrasound’/exp
OR (hyperthermi* OR thermotherap* OR ((therm* OR heat) NEAR/3 therap*) OR ((high-intensit*)
NEAR/3 ultras*)):ab,ti) AND (‘magnetic resonance thermometry’/exp OR ‘MR-guided focused ultra-
sound’/exp OR ((‘nuclear magnetic resonance’/exp OR ‘nuclear magnetic resonance imaging’/exp)
AND (‘thermometry’/de OR ‘temperature measurement’/de OR ‘thermometer’/de)) OR (((magnetic
OR proton*) NEAR/3 (resonance) NEAR/6 (thermometr* OR thermogra* OR guid* OR controlled*))
OR ((MR OR mri OR nmr OR MRT OR Prf) NEAR/6 (thermometr* OR thermogra* OR guid* OR con-
trolled*)) OR ((MR OR mri OR nmr OR MRT OR Prf) NEAR/6 (temperature* OR thermal*) NEAR/6
(mapping* OR map OR maps OR imag* OR measure* OR monitoring* OR dosing* OR dosage OR
value* OR change*)) OR ((magnetic OR proton*) NEAR/3 (resonance) NEAR/6 (temperature* OR
thermal*) NEAR/6 (mapping* OR map OR maps OR imag* OR measure* OR monitoring* OR dosing*
OR dosage OR value* OR change*))):ab,ti) NOT (‘ablation therapy’/exp/mj OR (ablation*):ti) NOT
([conference abstract]/lim) AND [English]/lim.
Appendix A.2. Medline ALL Ovid (1946–) 723
(Hyperthermia, Induced/ OR (hyperthermi* OR thermotherap* OR ((therm* OR heat) ADJ3
therap*) OR ((high-intensit*) ADJ3 ultras*)).ab,ti.) AND (((exp Magnetic Resonance Imaging/) AND
(exp Thermometry/ OR Thermometers/)) OR (((magnetic OR proton*) ADJ3 (resonance) ADJ6
(thermometr* OR thermogra* OR guid* OR controlled*)) OR ((MR OR mri OR nmr OR MRT OR
Prf) ADJ6 (thermometr* OR thermogra* OR guid* OR controlled*)) OR ((MR OR mri OR nmr OR
MRT OR Prf) ADJ6 (temperature* OR thermal*) ADJ6 (mapping* OR map OR maps OR imag* OR
measure* OR monitoring* OR dosing* OR dosage OR value* OR change*)) OR ((magnetic OR proton*)
ADJ3 (resonance) ADJ6 (temperature* OR thermal*) ADJ6 (mapping* OR map OR maps OR imag*
OR measure* OR monitoring* OR dosing* OR dosage OR value* OR change*))).ab,ti.) NOT (exp
*Ablation Techniques/OR (ablation*).ti.) NOT (news OR congres* OR abstract* OR book* OR chapter*
OR dissertation abstract*).pt. AND english.la.
Appendix A.3. Web of Science Core Collection (1975–) 693
AB = (((hyperthermi* OR thermotherap* OR ((therm* OR heat) NEAR/2 therap*) OR ((high-
intensit*) NEAR/2 ultras*))) AND ((((magnetic OR proton*) NEAR/2 (resonance) NEAR/5 (ther-
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mometr* OR thermogra* OR guid* OR controlled*)) OR ((MR OR mri OR nmr OR MRT OR Prf)
NEAR/5 (thermometr* OR thermogra* OR guid* OR controlled*)) OR ((MR OR mri OR nmr OR
MRT OR Prf) NEAR/5 (temperature* OR thermal*) NEAR/5 (mapping* OR map OR maps OR imag*
OR measure* OR monitoring* OR dosing* OR dosage OR value* OR change*)) OR ((magnetic OR
proton*) NEAR/2 (resonance) NEAR/5 (temperature* OR thermal*) NEAR/5 (mapping* OR map
OR maps OR imag* OR measure* OR monitoring* OR dosing* OR dosage OR value* OR change*)))))
NOT (TI = (ablation*)) AND DT = (article) AND LA = (english).
Appendix A.4. Cochrane CENTRAL Register of Trials (1992–) 21
((hyperthermi* OR thermotherap* OR ((therm* OR heat) NEAR/3 therap*) OR ((high-intensit*)
NEAR/3 ultras*)):ab,ti) AND ((((magnetic OR proton*) NEAR/3 (resonance) NEAR/6 (thermometr*
OR thermogra* OR guid* OR controlled*)) OR ((MR OR mri OR nmr OR MRT OR Prf) NEAR/6
(thermometr* OR thermogra* OR guid* OR controlled*)) OR ((MR OR mri OR nmr OR MRT OR
Prf) NEAR/6 (temperature* OR thermal*) NEAR/6 (mapping* OR map OR maps OR imag* OR
measure* OR monitoring* OR dosing* OR dosage OR value* OR change*)) OR ((magnetic OR proton*)
NEAR/3 (resonance) NEAR/6 (temperature* OR thermal*) NEAR/6 (mapping* OR map OR maps
OR imag* OR measure* OR monitoring* OR dosing* OR dosage OR value* OR change*))):ab,ti) NOT
((ablation*):ti).
Appendix A.5. Google Scholar 200
hyperthermia|thermotherapy “magnetic|proton resonance” thermometry|thermography|
“temperature|thermal mapping|map|measurement|monitoring”-ablation.
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